vs
Axsome Therapeutics, Inc.（AXSM）与MARCUS CORP（MCS）财务数据对比。点击上方公司名可切换其他公司
MARCUS CORP的季度营收约是Axsome Therapeutics, Inc.的1.0倍（$193.5M vs $191.2M），Axsome Therapeutics, Inc.同比增速更快（57.4% vs 2.8%），过去两年Axsome Therapeutics, Inc.的营收复合增速更高（48.1% vs 18.2%）
Jazz Pharmaceuticals是一家全球生物制药企业，专注于肿瘤学与神经科学领域的药物研发及商业化。公司2003年在美国加利福尼亚州成立，目前总部位于爱尔兰都柏林，业务覆盖全球多个核心市场。
马库斯公司是一家美国企业，主营商业地产领域相关服务，业务覆盖美国与加拿大，提供商业地产经纪、按揭经纪、行业研究以及咨询服务，首创了由单一经纪公司独家代理房源挂牌的行业模式，目前在美加两国设有超过80家办公室，拥有员工超1800名。
AXSM vs MCS — 直观对比
营收规模更大
MCS
是对方的1.0倍
$191.2M
营收增速更快
AXSM
高出54.7%
2.8%
两年增速更快
AXSM
近两年复合增速
18.2%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $191.2M | $193.5M |
| 净利润 | — | — |
| 毛利率 | — | — |
| 营业利润率 | -33.1% | 0.9% |
| 净利率 | — | — |
| 营收同比 | 57.4% | 2.8% |
| 净利润同比 | — | — |
| 每股收益（稀释后） | — | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AXSMMCS
| Q1 26 | $191.2M | — | ||
| Q4 25 | $196.0M | $193.5M | ||
| Q3 25 | $171.0M | $210.2M | ||
| Q2 25 | $150.0M | $206.0M | ||
| Q1 25 | $121.5M | $148.8M | ||
| Q4 24 | $118.8M | $188.3M | ||
| Q3 24 | $104.8M | $232.7M | ||
| Q2 24 | $87.2M | $176.0M |
净利润AXSMMCS
| Q1 26 | — | — | ||
| Q4 25 | $-28.6M | — | ||
| Q3 25 | $-47.2M | $16.2M | ||
| Q2 25 | $-48.0M | $7.3M | ||
| Q1 25 | $-59.4M | $-16.8M | ||
| Q4 24 | $-74.9M | $986.0K | ||
| Q3 24 | $-64.6M | $23.3M | ||
| Q2 24 | $-79.3M | $-20.2M |
营业利润率AXSMMCS
| Q1 26 | -33.1% | — | ||
| Q4 25 | -13.8% | 0.9% | ||
| Q3 25 | -27.0% | 10.8% | ||
| Q2 25 | -24.5% | 6.3% | ||
| Q1 25 | -46.9% | -13.7% | ||
| Q4 24 | -61.1% | -1.2% | ||
| Q3 24 | -59.8% | 14.1% | ||
| Q2 24 | -89.5% | 1.3% |
净利率AXSMMCS
| Q1 26 | — | — | ||
| Q4 25 | -14.6% | — | ||
| Q3 25 | -27.6% | 7.7% | ||
| Q2 25 | -32.0% | 3.6% | ||
| Q1 25 | -48.9% | -11.3% | ||
| Q4 24 | -63.1% | 0.5% | ||
| Q3 24 | -61.7% | 10.0% | ||
| Q2 24 | -91.0% | -11.5% |
每股收益（稀释后）AXSMMCS
| Q1 26 | — | — | ||
| Q4 25 | $-0.55 | — | ||
| Q3 25 | $-0.94 | — | ||
| Q2 25 | $-0.97 | — | ||
| Q1 25 | $-1.22 | — | ||
| Q4 24 | $-1.54 | — | ||
| Q3 24 | $-1.34 | — | ||
| Q2 24 | $-1.67 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $305.1M | $23.4M |
| 总债务越低越好 | $70.0M | $159.0M |
| 股东权益账面价值 | — | $457.4M |
| 总资产 | $713.6M | $1.0B |
| 负债/权益比越低杠杆越低 | — | 0.35× |
8季度趋势，按日历期对齐
现金及短期投资AXSMMCS
| Q1 26 | $305.1M | — | ||
| Q4 25 | $322.9M | $23.4M | ||
| Q3 25 | $325.3M | $7.4M | ||
| Q2 25 | $303.0M | $14.9M | ||
| Q1 25 | $300.9M | $11.9M | ||
| Q4 24 | $315.4M | $40.8M | ||
| Q3 24 | $327.3M | $28.4M | ||
| Q2 24 | $315.7M | $32.8M |
总债务AXSMMCS
| Q1 26 | $70.0M | — | ||
| Q4 25 | — | $159.0M | ||
| Q3 25 | — | $162.0M | ||
| Q2 25 | — | $179.9M | ||
| Q1 25 | — | $198.9M | ||
| Q4 24 | — | $159.1M | ||
| Q3 24 | — | $173.1M | ||
| Q2 24 | — | $175.7M |
股东权益AXSMMCS
| Q1 26 | — | — | ||
| Q4 25 | $88.3M | $457.4M | ||
| Q3 25 | $73.7M | $454.3M | ||
| Q2 25 | $73.1M | $448.4M | ||
| Q1 25 | $53.2M | $441.8M | ||
| Q4 24 | $57.0M | $464.9M | ||
| Q3 24 | $92.9M | $462.3M | ||
| Q2 24 | $102.9M | $449.4M |
总资产AXSMMCS
| Q1 26 | $713.6M | — | ||
| Q4 25 | $689.8M | $1.0B | ||
| Q3 25 | $669.3M | $1.0B | ||
| Q2 25 | $639.8M | $1.0B | ||
| Q1 25 | $596.7M | $1.0B | ||
| Q4 24 | $568.5M | $1.0B | ||
| Q3 24 | $561.5M | $1.0B | ||
| Q2 24 | $548.2M | $1.1B |
负债/权益比AXSMMCS
| Q1 26 | — | — | ||
| Q4 25 | — | 0.35× | ||
| Q3 25 | — | 0.36× | ||
| Q2 25 | — | 0.40× | ||
| Q1 25 | — | 0.45× | ||
| Q4 24 | — | 0.34× | ||
| Q3 24 | — | 0.37× | ||
| Q2 24 | — | 0.39× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $48.8M |
| 自由现金流经营现金流 - 资本支出 | — | $26.4M |
| 自由现金流率自由现金流/营收 | — | 13.6% |
| 资本支出强度资本支出/营收 | — | 11.6% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $989.0K |
8季度趋势，按日历期对齐
经营现金流AXSMMCS
| Q1 26 | — | — | ||
| Q4 25 | $-18.7M | $48.8M | ||
| Q3 25 | $1.0M | $39.1M | ||
| Q2 25 | $-32.4M | $31.6M | ||
| Q1 25 | $-43.4M | $-35.3M | ||
| Q4 24 | $-26.2M | $52.6M | ||
| Q3 24 | $-18.6M | $30.5M | ||
| Q2 24 | $-30.1M | $36.0M |
自由现金流AXSMMCS
| Q1 26 | — | — | ||
| Q4 25 | $-18.7M | $26.4M | ||
| Q3 25 | $988.0K | $18.2M | ||
| Q2 25 | $-32.4M | $14.7M | ||
| Q1 25 | $-43.7M | $-58.3M | ||
| Q4 24 | $-26.2M | $27.1M | ||
| Q3 24 | $-18.7M | $12.0M | ||
| Q2 24 | $-30.2M | $16.1M |
自由现金流率AXSMMCS
| Q1 26 | — | — | ||
| Q4 25 | -9.6% | 13.6% | ||
| Q3 25 | 0.6% | 8.7% | ||
| Q2 25 | -21.6% | 7.1% | ||
| Q1 25 | -36.0% | -39.2% | ||
| Q4 24 | -22.1% | 14.4% | ||
| Q3 24 | -17.9% | 5.2% | ||
| Q2 24 | -34.6% | 9.2% |
资本支出强度AXSMMCS
| Q1 26 | — | — | ||
| Q4 25 | 0.0% | 11.6% | ||
| Q3 25 | 0.0% | 9.9% | ||
| Q2 25 | 0.0% | 8.2% | ||
| Q1 25 | 0.3% | 15.5% | ||
| Q4 24 | 0.0% | 13.5% | ||
| Q3 24 | 0.1% | 7.9% | ||
| Q2 24 | 0.1% | 11.3% |
现金转化率AXSMMCS
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 2.41× | ||
| Q2 25 | — | 4.32× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 53.31× | ||
| Q3 24 | — | 1.31× | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AXSM
| Product sales, net | $189.4M | 99% |
| Royalty revenue and milestone revenue | $1.8M | 1% |
MCS
| Theatres | $123.1M | 64% |
| Concessions | $51.0M | 26% |
| Food And Beverage | $21.2M | 11% |
